What is the price per share for Maykin Ho’s BioMarin stock grant?

The filing shows a transaction price of $0.00 per share for the 7,490 shares acquired. A footnote explains these are restricted stock units granted on June 2, 2026, so a market purchase price is not applicable to this compensation-related award.

BioMarin director granted 7,490 restricted shares

BioMarin Pharmaceutical director Maykin Ho reported an equity grant of company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BioMarin Pharmaceutical director Maykin Ho reported an equity grant of company stock. On June 2, 2026, Ho acquired 7,490 shares of BioMarin common stock through a grant classified as restricted stock units, with no cash price per share.

Following this award, Ho directly holds 35,500 shares of BioMarin common stock. Because this was a compensation-related grant rather than an open-market trade, it mainly reflects ongoing equity-based director compensation rather than a change in personal investment stance.

Insider Trade Summary

Grant/Award: 7,490 shares

Grant/Award 1 txn

Insider Ho Maykin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	$0.00

Holdings After Transaction: Common Stock — 35,500 shares (Direct)

Footnotes (1)

F1. Restricted stock units granted on June 2, 2026. Price not applicable.

Key Figures

Shares granted: 7,490 shares Price per share: $0.00 per share Shares held after transaction: 35,500 shares

3 metrics

Shares granted 7,490 shares Restricted stock unit grant on June 2, 2026

Price per share $0.00 per share Reported for the 7,490-share grant

Shares held after transaction 35,500 shares Total direct holdings following the grant

Key Terms

Restricted stock units, Common Stock, Grant, award, or other acquisition

3 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioMarin (BMRN) director Maykin Ho report in this Form 4?

Director Maykin Ho reported receiving 7,490 shares of BioMarin common stock as a restricted stock unit grant on June 2, 2026. The award carried no cash purchase price and increased her direct holdings to 35,500 shares after the transaction.

Was the BioMarin (BMRN) Form 4 a stock purchase or a grant?

The Form 4 reflects a stock grant, not a market purchase. Maykin Ho acquired 7,490 shares through a restricted stock unit award, classified as a grant or other acquisition, with a transaction price of $0.00 per share reported in the filing.

How many BioMarin (BMRN) shares does Maykin Ho hold after this transaction?

After the June 2, 2026 restricted stock unit grant, Maykin Ho directly holds 35,500 shares of BioMarin common stock. This total includes the newly granted 7,490 shares reported as acquired in the non-derivative section of the Form 4.

Does this BioMarin (BMRN) Form 4 indicate any stock sales by Maykin Ho?

No, the Form 4 only reports an acquisition via a restricted stock unit grant. The transaction summary lists one acquisition event and zero sales or dispositions, and the total shares held directly increased to 35,500 shares after the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/04/2026 - 06:07 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ho Maykin

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

CALIFORNIA

94901

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/02/2026		A		7,490	A	$0⁽¹⁾	35,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR